Navigation Links
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Date:7/16/2008

"_new">http://www.cff.org ).

About PTC124

PTC124 is an orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely stop the translation process, preventing production of a functional protein. In Phase 2a clinical trials in nonsense-mutation-mediated cystic fibrosis (CF) and Duchenne muscular dystrophy (DMD), PTC124 has demonstrated the ability to produce protein across a variety of nonsense mutation types. Across all clinical studies to date, PTC124 has been generally well tolerated and has achieved target plasma concentrations that have been associated with activity in preclinical models. PTC124 is currently in Phase 2b development in DMD with the goal of demonstrating that increasing functional protein levels in patients with nonsense-mutation-mediated genetic disorders may provide clinical benefits.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation, the leading organization focused on curing and controlling cystic fibrosis, has invested nearly $300 million in drug research with biotech companies since 1998 to develop therapies to fight CF. As a result, the Foundation has built a drug pipeline with more than 30 promising therapies in development. Virtually all the approved CF therapies available today were made possible because of the support of the Foundation. Based in Bethesda, MD, the Foundation has 80 chapters and branch offices, and supports and accredits a nationwide network of 115 CF care centers that provide treatment and vital resources to patients and families. For more information visit http://www.cff.org

About PTC Therapeutics Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptiona
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Board Changes
5. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 19, 2014 Große ... Das Problem dabei ist, dass große Pharmafirmen ... Kompetenz zu teilen. Es war deshalb ... wir uns umso mehr, dass es uns gelungen ... bei Kühlketten aufzuschreiben - mit einem Vorbehalt - ...
(Date:10/17/2014)... , Oct. 17, 2014  Training market ... a critical success factor in today,s highly competitive ... market research organizations that effectively and efficiently produce ... or service area. Effective training ... and earn recognition from internal clients by developing ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US ... a leading online community and information resource for neurologists and ... and Alzheimer disease , with discussions of the ... 1 million Americans have Parkinson disease , more than ... or Lou Gehrig disease. Diagnosis can be difficult ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... An optimized PARI eFlow,platform nebulizer will be ... trial that has begun enrolling patients. ALN-RSV01 is ... respiratory syncytial virus,(RSV) infection, the leading cause of ... in immune-compromised adults. RSV currently does,not have a ...
... SGP ), a leader in advancing the ... infection, announced today that final,results of the IDEAL ... studies,with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP),combination ... for the,Study of the Liver (EASL) 43rd annual ...
Cached Medicine Technology:PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 9
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, ... and GreenGeeks are the best Dedicated Server Hosting ... who want to buy high quality hosting and ... IT manager of Top10BestSEOHosting.com says, “We believe that ... for everyone. A lot of the global clients ...
(Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... Citing persistent noncompliance and numerous performance deficiencies, the Department of ... a five-year, $75 million contract with the University of Texas ... Veterans, Illnesses (GWVI). , , "Research into ... for VA," said Dr. Gerald M. Cross, VA,s Acting Under ...
... , , , ... WASHINGTON, Aug. 26 Last night in northern Virginia, Representative James ... health care that was attended by thousands of people. Anti-abortion extremist ... the event that he would be there to disrupt it by ...
... Breast Cancer Metastasis Dr. Amanda Harvey and colleagues ... a role in breast cancer progression and dissemination. Their ... the American Journal of Pathology . ... breast cancer patients. Non-metastatic breast cancer cells rely on ...
... Singapore are reporting development of a new electronic sensor that ... alternative than tests now used to detect DNA. Such ... purposes. The new lab-on-a-chip test could lead to wider, more ... is scheduled for the Sept. 2 issue of the ...
... , Large variations exist in peoples, ability to eliminate arsenic ... existing standards for evaluating the human health risks from the ... more than 90 percent of the arsenic consumed in the ... have harmful effects. The research, based on the first application ...
... , PALM BEACH GARDENS, Fla., Aug. 26 The only effective ... from Chinese Drywall is now available. The RISS System(TM) removes the ... RISS system is so unique that it is in Patent Pending status with ... The RISS System(TM) : ( www.RISS s y s ...
Cached Medicine News:Health News:VA Continues Gulf War Research, Cancels Contract with UTSW Medical Center 2Health News:Randall Terry Removed By Police From Howard Dean Health Care Town Hall Meeting 2Health News:Tips from the American Journal of Pathology 2Health News:Tips from the American Journal of Pathology 3Health News:Tips from the American Journal of Pathology 4Health News:Tips from the American Journal of Pathology 5Health News:Proven Solution for Chinese Drywall is Now Available 2
... LactoSorb copolymer maintains almost all its mechanical ... mass loss in 915 months. Blunt thread ... Seventeen sizes to maximize surgeons options. ... entire screw to help prevent the screw ...
... The Asnis III™ Cannulated Screw System ... 2 and TCS Systems and combined them ... cannulated screws in both titanium and stainless ... Screw System is designed to optimize surgical ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
... The VersaNail System is a complete system ... to use with TTC fusion surgery. The ... specialists and integrates clinical research and engineering ... Because every patient is different, and because ...
Medicine Products: